Saturday 17 October 2026 Export BLTE’s income statement to Excel — free account

Belite Bio, Inc. Sponsored ADR

In the quarter to June 2026, EPS fell 40.0% and free cash flow grew 64.7%, each against the same quarter a year earlier.

142.78 9.84 −6.45%

Follow BLTE

Alert me

Market cap: $6.2B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 40.63

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	15	5	2	—	2	2	1

Insider Ownership 1.57%

Capital & Financial Ratios $m

Market Cap 6,150.00

Revenue —

Net Income (77.61)

Free Cash Flow (66.58)

Net Debt (492.42)

Current Ratio 33.56

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 7.45

Past 5Y EPS Growth —

This Y EPS Growth (37.66%)

Next Y EPS Growth 159.75%

Next Y revenue growth —

Next 5Y EPS Growth 39.91%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 7.75%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	88	145	492	—
Receivables	1	1	1	—
Inventory	—	—	—	—
Other	—	—	—	—
	90	147	494	502

	2023	2024	2025	Q'26
Payables	—	—	—	—
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	6	10	15

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	164.79%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	(27)	(10)	(37)
’24	—	—	(25)	(5)	(29)
’23	—	—	—	(30)	(30)
’22	—	0	0	(11)	(11)
’21	—	—	—	(7)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	(27)	(11)	(37)
’24	—	—	(25)	(5)	(29)
’23	—	—	—	(30)	(30)
’22	—	0	0	(12)	(12)
’21	—	—	—	(8)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.68)	(0.70)	—	—	—
’25	(0.45)	(0.50)	(0.65)	(0.70)	(2.31)
’24	(0.27)	(0.31)	(0.28)	(0.32)	(1.18)
’23	(0.33)	(0.26)	(0.40)	(0.25)	(1.19)
’22	—	(0.12)	(0.10)	—	(0.65)
’21	—	—	—	—	(1.01)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	8.80	11.00	31.01	49.00	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	44.70	46.70	86.53	169.75
People
People	Employees	—	—	—	—	—	12	16	20	25	23
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	—	(6)	(10)	(13)	(32)	(36)	(78)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	(6)	(10)	(13)	(32)	(36)	(78)
	Depreciation	—	—	—	—	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	(0.65)	(1.01)	(0.65)	(1.19)	(1.18)	(2.31)
	Cash flow	—	—	—	—	(0.51)	(0.78)	(0.57)	(1.12)	(0.96)	(1.10)
	Capex	—	—	—	—	0.00	(0.01)	(0.02)	0.00	0.00	(0.01)
	Free cash flow	—	—	—	—	(0.51)	(0.79)	(0.59)	(1.12)	(0.96)	(1.11)
	Book value	—	—	—	—	(0.80)	(1.58)	2.08	3.40	4.78	22.97
	Shares, m	—	—	—	—	9	10	20	27	31	34
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	(4)	(7)	(11)	(30)	(29)	(37)
	Capex	—	—	—	—	0	0	0	0	0	0
	Free cash flow	—	—	—	—	(4)	(8)	(12)	(30)	(29)	(37)
Balance, $m
Balance, $m	Working capital	—	—	—	—	25	16	41	86	141	484
	Total debt	—	—	—	—	32	32	1	—	—	—
	Net debt	—	—	—	—	(26)	(17)	(42)	(88)	(145)	(492)
	Shareholders’ equity	—	—	—	—	(7)	(15)	42	90	146	770
Returns, %
Returns, %	ROA	—	—	—	—	0.00	(43.85)	(40.40)	(45.54)	(29.29)	(16.64)
	ROIC	—	—	—	—	0.00	0.00	0.00	(870.38)	(3,719.87)	(18.93)
	ROE	—	—	—	—	0.00	87.36	(95.79)	(47.95)	(30.60)	(16.94)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PRAX Praxis Precision Medicines, Inc.	$6.9B	— (loss-making)	— (loss-making)	+1,349.13% (above 0%: growing)	n/m	−43.54% (below 0%: shrinking)	100.00%	0.00%	Compare
IOVA Iovance Biotherapeutics, Inc.	$6.7B	— (loss-making)	— (loss-making)	+65.65% (above 0%: growing)	n/m	+11.52% (above 0%: growing)	56.10%	(52.26%)	Compare
BLTE Belite Bio, Inc. Sponsored ADR	$6.2B	— (loss-making)	—	—	n/m	+64.67% (above 0%: growing)	—	0.00%
RYTM Rhythm Pharmaceuticals, Inc.	$6.1B	— (loss-making)	— (loss-making)	+46.91% (above 0%: growing)	n/m	+60.74% (above 0%: growing)	87.47%	(68.14%)	Compare
LGND Ligand Pharmaceuticals Incorporated	$6.0B	29.5×	54.7×	+33.73% (above 0%: growing)	+868.00% (above 0%: growing)	+35.53% (above 0%: growing)	94.95%	13.49%	Compare
IMVT Immunovant, Inc.	$5.7B	— (loss-making)	—	—	n/m	−5.96% (below 0%: shrinking)	0.00%	0.00%	Compare
KOD Kodiak Sciences Inc.	$5.5B	— (loss-making)	—	—	n/m	−33.86% (below 0%: shrinking)	0.00%	0.00%	Compare
CGON CG Oncology, Inc.	$5.5B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
Median of peers	$5.8B	—	—	+56.28%	—	−19.91%	69.44%	(12.07%)

All 614 Biotechnology stocks →

Belite Bio, Inc. Sponsored ADR (BLTE) key facts

Concern: Belite Bio, Inc. Sponsored ADR reported a net loss of $77.6 million, or a loss of $2.31 per share, for fiscal 2025.
Belite Bio, Inc. Sponsored ADR (BLTE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BLTE traded at $142.78, a market capitalization of $6.2 billion.
Return on equity was −16.9% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.